Pacira Pharma Swings To Profit In Q4 - Quick Facts

(RTTNews) - Specialty pharmaceutical company Pacira Pharmaceuticals, Inc. (PCRX) reported fourth-quarter net income of $5.80 million or $0.14 per share, compared to net loss of $11.96 million or $0.36 per share in the year-ago period.

Adjusted earnings for the quarter were $0.35 per share, compared to adjusted loss of $0.23 per share in the year-ago period.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.27 per share for the quarter for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter surged to $61.79 million from $33.56 million in the year-ago period. Analysts had a consensus revenue estimate of $62.10 million for the quarter.

Looking ahead to fiscal 2015, Pacira forecast Exparel revenues of $310 million to $330 million, with about 10 percent of these projected revenues coming from the pending nerve block indication.

The outlook includes the assumption that the company will obtain a nerve block indication by the Prescription Drug User Fee Act or PDUFA target date of March 5.

Street expects the company to report revenues of $333.25 million for the year.